Mizuho raised the firm’s price target on Sage Therapeutics to $20 from $19 and keeps a Neutral rating on the shares. The analyst reduced research and development estimates for 2023 and beyond to take into consideration details from the company’s reorganization plan. However, the firm still sees a lack of clarity on the steps forward for Zurzuvae.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SAGE:
- Sage Therapeutics price target lowered to $24 from $28 at TD Cowen
- Sage Therapeutics price target raised to $27 from $24 at Scotiabank
- Sage Therapeutics (NASDAQ:SAGE) Slashes 40% of Positions with Zurzuvae Launch in Mind
- Sage Therapeutics announces changes to leadership team
- Sage Therapeutics announces plans to reorganize business operations
